{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"STRIKE","nct_id":"NCT06661720","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=strike-nct06661720. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"STRIKE","arms":[{"description":"Patients receive pembrolizumab IV on days 1 and 43 of each cycle, or on days 1, 22, 43 and 64 of each cycle. Cycles repeat every 12 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI or CT throughout the trial and may undergo tissue biopsy on study.","label":"Arm 1 (Pembrolizumab)","type":"ACTIVE_COMPARATOR"},{"description":"Patients receive pembrolizumab IV on days 1 and 43 of each cycle and tivozanib PO QD on days 1-21, days 29-49, and days 57-77 of each cycle for up to 6 months. Cycles repeat every 12 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI or CT throughout the trial and may undergo tissue biopsy on study.","label":"Arm 2 (pembrolizumab + tivozanib)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2037-11","type":"ESTIMATED"},"conditions":["Clear Cell Renal Cell Carcinoma","Renal Cell Carcinoma (RCC)","Stage II Renal Pelvis Cancer AJCC v8","Stage III Renal Pelvis Cancer AJCC v8"],"enrollment":{"count":1040,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":["Keytruda"],"type":"BIOLOGICAL"},{"name":"Tivozanib","otherNames":[],"type":"DRUG"},{"name":"Biospecimen Collection","otherNames":[],"type":"PROCEDURE"},{"name":"MRI","otherNames":[],"type":"PROCEDURE"},{"name":"Computed Tomography","otherNames":["CT Scan","CAT Scan"],"type":"PROCEDURE"},{"name":"Biopsy","otherNames":[],"type":"PROCEDURE"},{"name":"Questionnaire Administration","otherNames":[],"type":"OTHER"}],"last_update":"2026-11-03","lead_sponsor":"Alliance for Clinical Trials in Oncology","official_title":"Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2037-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease-free survival (DFS)","timeFrame":"From time of randomization until disease recurrence or death, assessed up to 10 years"}],"references":[],"start_date":{"date":"2025-03-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer","url":"https://clinicaltrials.gov/study/NCT06661720"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/strike-nct06661720"}